Search

This scoping review aims to document Chinese Patent Medicines (CPMs) for Type 2 Diabetes Mellitus, explore whether CPMs can improve patients' health outcomes, and set priorities in addressing research gaps in this area. Following the framework of PRISMA-SCr, we proposed the research questions based on PICOS principle, and searched the CPMs for T2DM from three drug lists, followed by a systematic search of the literature in eight databases from their inception to June 22, 2023. Then, we developed the eligibility criteria and systematically reviewed the relevant studies, retained the studies about CPMs for T2DM, extracted the related data, and identified the differences across studies in structured charts. A total of 25 types of CPMs were extracted from the three drug lists. Radix astragali appeared most frequently (19 times) among the herbal medicinal ingredients of CPMs. A total of 449 articles were included in the full-paper analysis ultimately, all of which were about 20 types of CPMs, and there were no related reports on the remaining five CPMs. Except about a quarter (25.39 %, 114/449) using CPMs alone, the remaining studies all involved the combination with oral hypoglycemics for T2DM. Biguanides are the most common drugs used in combination with CPMs (50.14 %, 168/335). Fasting plasma glucose (FPG) is the most frequently reported outcomes in efficacy evaluation (82.41 %, 370/449). There are a total of 25 types of CPMs currently available for T2DM patients. However, the volume of related evidence on these CPMs varies. It is necessary to standardize the combined use of CPMs and conventional medicine and select appropriate outcomes in future studies. [ABSTRACT FROM AUTHOR]

In China, the clinical use of Chinese patent medicines (CPMs) for children with respiratory and/or digestive diseases (RDDs) is increasing, and there are many clinical studies on CPMs. However, little is known about the overall impact of CPMs on RDDs and co-morbid RDDs. Thus, this scoping review will aim to systematically identify and map available research evidence on CPMs for children with RDDs and co-morbid RDDs, explore the research gaps and drive further research. The scoping review will be conducted based on the framework proposed by Arksey and O'Malley, and reported following the standards of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). Both Chinese and international literature databases will be searched to identify eligible studies and other publicly available documents. Data will be analyzed using descriptive statistics and organized in response to review questions. Findings will be presented in a visual and aggregate form as well as a descriptive format aligning with the objectives and scope of this protocol. A dedicated article will be drafted to reflect the profile of the use of CPMs and research stemming from this protocol. The findings of the review will extend beyond previous reviews, and attempt to provide comprehensive insight into the role of CPMs in treating children with RDDs and co-morbid RDDs. [ABSTRACT FROM AUTHOR]